Objective: Relapse and lung metastasis of atypical type A thymoma are knotty problems in clinical treatment. The identification of specific biomarkers and novel therapeutic targets is critical for advancing the precision and efficacy of interventions against this disease. MicroRNAs (miRNAs), as pivotal regulators of gene expression, have emerged as key players in tumorigenesis and metastatic processes. In this study, we found that miR5700 was overexpressed in atypical type A thymoma, and miR5700 overexpression could promote lung cancer cell proliferation, migration, and invasion abilities. It gives us a clue that miR5700 could be a biomarker and therapeutic target for atypical type A thymoma.
Methods: miRNA microarray chip technology was applied to identify differentially expressed miRNAs in 20 pairs of atypical type A thymoma versus type A thymoma. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to detect the expression of miR5700 in non-small cell lung cancer cells after lentiviral transfection. Subsequently, cell proliferation was examined by the real-time cellular analysis and clone formation assay. Cell migration and invasion abilities were evaluated by wound healing and Matrigel transwell assay, respectively. Besides, the effect of miR5700 on AKT, mTOR, and β-catenin was determined by western blotting.
Results: MiR5700 was dramatically increased in atypical A thymoma. The transfection of miR5700 into A549 and H2170 cells significantly promoted cell growth, migration, and invasion. Furthermore, miR5700 was confirmed to upregulate the expression of AKT, mTOR and β-catenin proteins, which were related to tumour progression by western blotting.
Conclusions: High expression of miR5700 is a new hallmark that could promote tumour progression. Additionally, it is hoped that miR5700 will become a potential target for the diagnosis of atypical type A thymoma through further research in the future.
| [1] |
Strobe P, Marx A, Badve S, Chan JKC, Chen G, Detterbeck F. Type A thymoma, including atypical variant. in: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. IARC; 2015: 187-192. ISBN 978 92 832 2436 5.
|
| [2] |
Weissferdt A, Moran CA. Atypical thymoma (epithelial-rich thymoma, well-differentiated thymic carcinoma, WHO type B3 thymoma): a conundrum. Pathol Res Pract. 2023; 245:154459.
|
| [3] |
Roden AC, Walkoff LA, Saddoughi SA. Type A Thymoma. Mayo Clin Proc. 2025; 100(3): 499-500.
|
| [4] |
Williams AE. Functional aspects of animal microRNAs. Cell Mol Life Sci. 2008; 65(4): 545-562.
|
| [5] |
Kim VN, Han J, MC Siomi. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 10(2): 126-139.
|
| [6] |
Enkner F, Pichlhofer B, Zaharie AT, et al. Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets. Pathol Oncol Res. 2017; 23(3): 551-564.
|
| [7] |
Radovich M, Solzak JP, Hancock BA, et al. A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas. Br J Cancer. 2016; 114(4): 477-484.
|
| [8] |
Ganci F, Vico C, Korita E, et al. MicroRNA expression profiling of thymic epithelial tumors. Lung Cancer. 2014; 85(2): 197-204.
|
| [9] |
Rosado-de-Christenson ML, Galobardes J, Moran CA. Thymoma: radiologic-pathologic correlation. Radiographics. 1992; 12(1): 151-168.
|
| [10] |
Bogot NR, Quint LE. Imaging of thymic disorders. Cancer Imaging. 2005; 5: 139-149.
|
| [11] |
Benveniste MF, Rosado-de-Christenson ML, Sabloff BS, Moran CA, Swisher SG, Marom EM. Role of imaging in the diagnosis, staging, and treatment of thymoma. Radiographics. 2011; 31(7): 1847-1861. discussion 1861-1843.
|
| [12] |
de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer. 2008; 44(1): 123-130.
|
| [13] |
Nonaka D, Rosai J. Is there a spectrum of cytologic atypia in type A thymomas analogous to that seen in type B thymomas? A pilot study of 13 cases. Am J Surg Pathol. 2012; 36(6): 889-894.
|
| [14] |
Vladislav IT, Gokmen-Polar Y, Kesler KA, Loehrer PJ, Badve S. The role of histology in predicting recurrence of type A thymomas: a clinicopathologic correlation of 23 cases. Mod Pathol. 2013; 26(8): 1059-1064.
|
| [15] |
Masaoka A. Staging system of thymoma. J Thorac Oncol. 2010; 5(10 Suppl 4): S304-312.
|
| [16] |
Bian D, Zhou F, Yang W, et al. Thymoma size significantly affects the survival, metastasis and effectiveness of adjuvant therapies: a population based study. Oncotarget. 2018; 9(15): 12273-12283.
|
| [17] |
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5): 843-854.
|
| [18] |
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2): 281-297.
|
| [19] |
Bellissimo T, Russo E, Ganci F, et al. Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors. Cancer Biol Ther. 2016; 17(1): 79-82.
|
| [20] |
Weber K, Rostert N, Bauersachs S, Wess G. Serum microRNA profiles in cats with hypertrophic cardiomyopathy. Mol Cell Biochem. 2015; 402(1-2): 171-180.
|
| [21] |
Watahiki A, Wang Y, Morris J, et al. MicroRNAs associated with metastatic prostate cancer. PLoS One. 2011; 6(9):e24950.
|
| [22] |
Morishima Y, Satoh H, Ohtsu I, et al. Thymoma associated with pure red cell aplasia and lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi. 1996; 34(2): 236-240.
|
| [23] |
Shimada T, Terashima H, Shimizu T, Hirayama K. Invasive thymoma associated with lung cancer: report of a case. Surg Today. 2001; 31(6): 507-509.
|
RIGHTS & PERMISSIONS
2025 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
PDF
